5th edition of the 2022 WHO classification of prostate cancer: changes and novelties in the "Blue Book"

1. Amin MB, Kench JG, Rubin MA, Srigley JR, Tsuzuki T. Chapter 4: Tumours of the prostate. In: WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 8). https://publications. iarc.fr/610.

2. Kaur HB, Salles DC, Paulk A, Epstein JI, Eshleman JR, Lotan TL. PIN‑like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology. 1. leden 2021; 78(2): 327–33.

3. Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med. 1. duben 2021; 145(4): 461–93.

4. McNeal J, Yemoto C. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol. 1996; 20(7): 802–14.

5. Lotan TL, Gumuskaya B, Rahimi H, et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high‑grade prostatic intraepithelial neoplasia. Mod Pathol. 2013; 26(4): 587–603.

6. Dinerman BF, Khani F, Golan R, et al. Population‑based study of the incidence and survival for intraductal carcinoma of the prostate. Urol Oncol Semin Orig Investig. 2017; 35(12): 673.e9-673.e14.

7. van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol [Internet]. 2020; 44(8). Available from: https://journals.lww.com/ajsp/Fulltext/2020/08000/The_2019_International_Society_ of_Urological.1.aspx.

8. Sæter T, Vlatkovic L, Waaler G, et al. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population‑Based Study. The Prostate. 2017; 77(8): 859–65.

9. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol [Internet]. 2016; 40(2). Available from: https://journals. lww.com/ajsp/Fulltext/2016/02000/The_2014_International_Society_of_Urological.10.aspx.

10. Kato M, Tsuzuki T, Kimura K, et al. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol. 2016; 29(2): 166–73.

11. Netto GJ, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs – Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022; 82(5): 469–82. 12

ckman RA, Yu H, Li J, et al. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate. Am J Surg Pathol [Internet]. 2017; 41(4). Available from: https://journals.lww.com/ajsp/Fulltext/2017/04000/Atypical_Intraductal_ Cribriform_Proliferations_of.14.aspx.

13. Destouni M, Lazaris AC, Tzelepi V. Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance. Cancers. 2022; 14(13).

14. Seipel AH, Wiklund F, Wiklund NP, Egevad L. Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch. 2013; 462(4): 429–36.

15. Vinceneux A, Bruyère F, Haillot O, et al. Ductal adenocarcinoma of the prostate: Clinical and biological profiles. The Prostate. 2017; 77(12): 1242–50.

16. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol Off J U S Can Acad Pathol Inc. 2009/01/16 vyd. 2009; 22(3): 359–65.

17. Schweizer MT, Antonarakis ES, Bismar TA, et al. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precis Oncol. 2019; (3): 1–9.

18. Morgan TM, Welty CHJ, Funda VL, Lin DW, Wright. Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen. J Urol. 2010; 184(6): 2303–7.

19. Epstein JI, Allsbrook WCJ, Amin MB, Egevad LL, and the ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol [Internet]. 2005; 29(9). Available from: https://journals.lww.com/ajsp/Fulltext/ 2005/09000/The_2005_International_Society_of_Urological.15.aspx.

20. Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer Oxf Engl 1990. 2019; 121: 7–18.

21. Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and Genomic Characterization of Treatment‑Emergent Small‑Cell Neuroendocrine Prostate Cancer: A Multi‑institutional Prospective Study. J Clin Oncol. 2018; 36(24): 2492–503.

22. Bluemn EG, Coleman IM, Lucas JM, et al. Androgen Receptor Pathway‑Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017; 32(4): 474–489.e6.

23. Wang HT, Yao YH, Li BG. Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis – A Systematic Review and Pooled Analysis. J Clin Oncol. 2014; 32(30): 3383–90.

24. Park JW, Lee JK, Sheu KM, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018; 362(6410): 91–5.

25. Epstein JI, Amin MB, Beltran H, et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. Am J Surg Pathol. 2014; 38(6): 756–67.

26. Magers MJ, Iczkowski KA, Montironi R, et al. MYB‑NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Mod Pathol. 2019; 32(11): 1666–74.